Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice

Neutralizing antibodies represent a valuable therapeutic approach to countermeasure the current COVID-19 pandemic. Emergence of SARS-CoV-2 variants emphasizes the notion that antibody treatments need to rely on highly neutralizing monoclonal antibodies (mAbs), targeting several distinct epitopes for...

Descripción completa

Detalles Bibliográficos
Autores principales: Noy-Porat, Tal, Mechaly, Adva, Levy, Yinon, Makdasi, Efi, Alcalay, Ron, Gur, David, Aftalion, Moshe, Falach, Reut, Leviatan Ben-Arye, Shani, Lazar, Shirley, Zauberman, Ayelet, Epstein, Eyal, Chitlaru, Theodor, Weiss, Shay, Achdout, Hagit, Edgeworth, Jonathan D., Kikkeri, Raghavendra, Yu, Hai, Chen, Xi, Yitzhaki, Shmuel, Shapira, Shmuel C., Padler-Karavani, Vered, Mazor, Ohad, Rosenfeld, Ronit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074524/
https://www.ncbi.nlm.nih.gov/pubmed/33937725
http://dx.doi.org/10.1016/j.isci.2021.102479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074524/
https://www.ncbi.nlm.nih.gov/pubmed/33937725
http://dx.doi.org/10.1016/j.isci.2021.102479

Ejemplares similares